Imagine diagnosing cancer, even what specific type of cancer, non-invasively. This is especially important in the Lung, where biopsies and surgeries have high morbidity and mortality rates. RevealDx is a Seattle-based software company whose mission is dramatically improve lung cancer outcomes using non-invasive diagnosis. We are delivering the most advanced, radiomics and AI-enabled, lung cancer decision support software in the world. Click below to learn more.
Clinicians can be confident that their performance will be better if they include mSI in their assessment.
A single click is all that is needed to compute the mSI, and the results are displayed within a few seconds.
Cost can be dramatically decreased by reducing unnecessary procedures.
Seattle, WA – February 3, 2026 – RevealDx, a leader in AI tools for the characterization of lung nodules, announced FDA clearance of RevealAI-Lung. The company had previously announced MDR Certification in November of 2025. The RevealDx technology characterizes incidental lung nodules by producing a Malignancy Similarity Index (mSI™), a score that is intended to … RevealDx Receives FDA Clearance for AI Powered Lung Nodule Risk Assessment
[ MORE ]RDX clinical radiology pub
[ MORE ]
